Argenx highlights data showing patient impact across multiple immunology programs at 2024 american association of neuromuscular & electrodiagnostic medicine annual meeting and myasthenia gravis foundation of america scientific sessions

Long-term and real-world data of vyvgart® (efgartigimod alfa-fcab) and vyvgart® hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrate speed of onset, depth of response, and durability of response
ARGX Ratings Summary
ARGX Quant Ranking